<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179045</url>
  </required_header>
  <id_info>
    <org_study_id>BXA 2019001</org_study_id>
    <nct_id>NCT04179045</nct_id>
  </id_info>
  <brief_title>A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System</brief_title>
  <official_title>A Registry Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART Ⅲ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bio-heart Biological Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CCRF Inc., Beijing, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Bio-heart Biological Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multi-center single arm registry trial, planning to enroll 785
      subjects. All subjects will receive clinical follow-up at 1 month, 6 month, 9 month and 1, 2,
      3, 4, 5 year after index procedure. The primary endpoint will be target lesion failure (TLF)
      at 1 year after index procedure,which will be analyzed to evaluate the efficacy and safety of
      the device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TLF</measure>
    <time_frame>1 year after index procedure</time_frame>
    <description>Target lesion failure, consists of cardiac death, MI attributed to the target vessel, and ischemic driven - target lesion revascularization (ID-TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The device-oriented composite（DoCE） / TLF</measure>
    <time_frame>at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure</time_frame>
    <description>consists of cardiac death, MI attributed to the target vessel, and ischemic driven- target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient-oriented composite（PoCE）</measure>
    <time_frame>at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure</time_frame>
    <description>includes all-cause mortality, any MI, and any revascularization. Death（Cardiac death，Vascular death，Non-cardiovascular death）; Myocardial Infarction (target vessel MI, non-target vessel MI); Target lesion Revascularization（ischemic driven, non-ischemic driven） target vessel Revascularization （ischemic driven, non-ischemic driven）; Any Revascularization （ischemic driven, non-ischemic driven）.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis（ARC）</measure>
    <time_frame>at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure</time_frame>
    <description>Timing：Acute, Subacute, Late,Very late stent thrombosis Definite and Probable Stent Thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>immediately after index procedure</time_frame>
    <description>defined as attainment of residual stenosis less than 30% by visual estimation and TIMI flow grade 3 post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success</measure>
    <time_frame>immediately after index procedure</time_frame>
    <description>defined as attainment of diameter residual stenosis less than 30% by visual estimation and TIMI flow grade 3, after the target lesion treated by any PCI methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>up to 7 days after index procedure</time_frame>
    <description>defined as attainment of lesion success and without any major adverse cardiac events during hospitalization (up to 7 days after index procedure)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">785</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bioheart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have CAD with one or two de novo native coronary artery lesions and will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System. There will be only one arm in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System</intervention_name>
    <description>Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.</description>
    <arm_group_label>Bioheart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria:

          1. Age from 18 to 75 years old, man or non-pregnant woman.

          2. Subjects with asymptomatic ischemic evidence, stable or unstable angina, or old
             myocardial infarction, are suitable for selective PCI.

          3. Subjects without contraindications of coronary artery bypass grafting (CABG).

          4. Subjects are able to understand the purpose of this study, volunteer to participate
             and sign informed consent.

        Angiographic Inclusion Criteria:

          1. One or two de novo target lesions

               1. If subject has only one target lesion, the second non-target lesion must be
                  treated but the non-target lesion must be present in a different epicardial
                  vessel; the non target lesion must be treated first and successfully prior to the
                  subjects' register.

               2. If there are two target lesions, they must be present in different epicardial
                  vessels.

               3. The definition of epicardial vessels means the left anterior descending artery
                  (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and
                  their branches. Thus, for example, the subject must not have lesions requiring
                  treatment in both the LAD and a branch.

          2. Target lesion diameter stenosis is estimated visually ≥ 70% (or ≥ 50% with clinical
             evidence of myocardial ischemia), with TIMI flow grade ≥1; Target lesion length ≤24mm
             (visually); target lesion diameter between ≥2.5 mm to ≤ 4.00 mm.

          3. Each target lesion must be covered completely by one scaffold.

        Exclusion Criteria:

        General Exclusion Criteria:

          1. Any newly onset acute myocardial infarction within 1 week or, myocardial enzymes does
             not return to normal level after myocardial infarction.

          2. Target vessel has been implanted with stents within 1 year before procedure.

          3. Subjects with severe heart failure (≥ grade III NYHA) or left ventricular ejection
             fraction &lt;35% (accessed by ultrasound or left ventricular angiography).

          4. subject with severe kidney functional damaged before procedure: serum creatinine&gt;2.0mg
             /dl (176.8μmol / L) or subject is receiving hemodialysis.

          5. Subjects with high bleeding risk, with active gastrointestinal ulcers, history of
             cerebral hemorrhage or history of subarachnoid hemorrhage, history of ischemic stroke
             within the past six months, with contraindications of anti-platelet agents and
             anticoagulants, and subjects cannot receive antithrombolytic therapy.

          6. subject is known hypersensitive or allergic to aspirin, clopidogrel, heparin, contrast
             agent, polylactic acid polymer and rapamycin.

          7. The subject's life expectancy is less than 24 months.

          8. Subjects is currently participating in other drug or medical device clinical trial
             that has not yet completed its primary endpoint .

          9. Subjects have received any solid organ transplants or are ready to undergo organ
             transplant.

         10. Subjects have unstable arrhythmia, such as high-risk ventricular premature beats, and
             ventricular tachycardia.

         11. Subjects receive chemotherapy for tumor.

         12. Subjects have received or planning to receive coronary or chest radiotherapy.

         13. Subjects with Immunosuppressive, autoimmune diseases, have planned to receive or
             underwent immunosuppressive therapy.

         14. Subjects have planned to receive or are receiving long-term anticoagulation therapy,
             such as heparin, warfarin and so on.

         15. Subjects have planned to receive selective surgery within 6 months, which requires
             them to discontinue aspirin or clopidogrel.

         16. Blood tests showed that the platelet count is less than 100 × 10^9 / L, or more than
             700 × 10^9 / L, the white blood cells count is less than 3 × 10^9 /L.

         17. subject with diagnosed or suspected liver cirrhosis.

         18. Subjects with diffuse peripheral vascular disease, that precludes safe 6 French sheath
             insertion.

        Angiographic exclusion criteria:

        These exclusion criteria apply to the target or non-target lesion(s), target or non-target
        vessel(s):

          1. Target or non-target lesion(s) located in left main.

          2. Subjects with triple vessel lesion in LAD, LCX or RCA, which all need to be treated.

        These exclusion criteria apply to the target lesion(s) or target vessel(s):

          1. Target lesion located in left main.

          2. Target lesion located in the aorto-ostial of RCA (within 3 mm of the origin of the
             RCA).

          3. Target lesion located within 3 mm of the origin of the LAD and LCX.

          4. Lesion involving a bifurcation with a:

               1. Side branch ≥ 2.5 mm in diameter, or

               2. Side branch with diameter stenosis ≥ 50%, or

               3. Side branch requiring protection guide wire, or

               4. Side branch requiring pre-dilatation.

          5. Anatomy proximal to or within the lesion that may affect delivery of the Bioheart,
             including:

               1. Extreme angulation (≥ 90°) proximal to or within the target lesion, or

               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion,
                  or

               3. Moderate or heavy calcification proximal to or within the target lesion.

          6. Target lesion involves a myocardial bridge.

          7. Target vessel contains thrombus as indicated in the angiographic images or IVUS.

          8. Prior to the index procedure target vessel has been previously treated with a stent at
             any time such that the Bioheart stent would need to cross the stent to reach the
             target lesion.

          9. Target vessel has been previously treated with a stent and the target lesion is within
             5 mm proximal to a previously treated lesion.

         10. Target lesion cannot meet the following outcomes, after the complete balloon
             pre-dilatation:

               1. Residual (DS %) is &lt; 40% (per visual estimation), ≤ 20% is strongly recommended;

               2. TIMI Grade-3 flow (per visual estimation);

               3. No angiographic complications (e.g., no-reflow, distal embolization, side branch
                  closure)

               4. No dissections NHLBI grade D-F;

               5. No chest pain lasting &gt; 5 minutes, and;

               6. No ST depression or elevation lasting &gt; 5 minutes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shubin Qiao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shubin Qiao, Professor</last_name>
    <phone>+8610-88398065</phone>
    <email>qsbfw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BeijingChao-YangHospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfnag Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Dongfang Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taida International Cardioascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 24, 2019</last_update_submitted>
  <last_update_submitted_qc>November 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioresorbable Vascular Scaffold System</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

